Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound.
Authors: Poon C, McMahon D, Hynynen K
The range of therapeutic treatment options for central nervous system (CNS) diseases is greatly limited by the blood-brain barrier (BBB). While a variety of strategies to circumvent the blood-brain barrier for drug delivery have been investigated, little clinical success has been achieved. Focused ultrasound (FUS) is a unique approach whereby the transcranial application of acoustic energy to targeted brain areas causes a noninvasive, safe, transient, and targeted opening of the BBB, providing an avenue for the delivery of therapeutic agents from the systemic circulation into the brain. There is a great need for viable treatment strategies for CNS diseases, and we believe that the preclinical success of this technique should encourage a rapid movement towards clinical testing. In this review, we address the versatile applications of FUS-mediated BBB opening, the safety profile of the technique, and the physical and biological mechanisms that drive this process. This article is part of the Special Issue entitled "Beyond small molecules for neurological disorders".
Introduction
Purpose
Drug delivery with BBB opening
Outcomes and Safety
Summary of Outcomes
Focused ultrasound combined with microbubbles enables noninvasive, targeted, reversible opening of the blood-brain barrier, allowing delivery of diverse therapeutics (chemotherapeutics, antibodies, viral vectors, stem cells) to the brain. Preclinical studies demonstrate safety when using optimized parameters (e.g., mechanical index ~0.46), with BBB closure within 1-10 hours and no long-term damage. First clinical trial for BBB opening in brain tumors is underway.
Brain Region
Targeted brain region(s)
Not specified
Ultrasound Parameters
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search